Eli Lilly and Company moved -2.3% this afternoon session, trading between a high of $537.29 and a low of $516.57 per share. Yesterday the stock finished at $538.29 per share, compared to an average analyst target price of $574.9.
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The large-cap biotechnology: pharmaceutical preparations company is based in the United States, and over the last twelve months it has returned a dividend yield of 0.8%. Eli Lilly and Company has trailing twelve months earnings per share (EPS) of 7.2, which at today's prices amounts to a price to earnings (P/E) ratio of 73.1.
Based on its expected future earnings growth, the company has a price to earnings growth (PEG) ratio of 2.26. Usually a PEG ratio between 0 and 1 indicates a potentially undervalued company.
Overview of the Company's Gross Margins:
| Date Reported | Revenue ($ k) | Cost of Revenue ($ k) | Gross Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2023-02-22 | 28,541,400 | -6,629,800 | 77 | 4.05 |
| 2022-02-23 | 28,318,400 | -7,312,800 | 74 | -5.13 |
| 2021-02-17 | 24,539,800 | -5,483,300 | 78 | -1.27 |
| 2020-02-19 | 22,319,500 | -4,721,200 | 79 | 1.28 |
| 2019-02-19 | 21,493,300 | -4,681,700 | 78 | 6.85 |
| 2018-02-20 | 22,871,300 | -6,150,800 | 73 |
At 76.5%, Eli Lilly and Company's average gross margins are wider than the 60.94% average of its industry peer group, which suggests that the firm might have a competitive advantage.
